Shao-Lee Lin

CIK: 0001725092

Transaction Breakdown

Open Market Buys (P)2 (13.3%)

High conviction signal

Open Market Sales (S)7 (46.7%)

Position reduction

Option Exercises (M)1 (6.7%)

Derivative conversions

Awards (A)5 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CUE

Cue Biopharma, Inc.

DirectorOfficer

SRZN

Surrozen, Inc./DE

Director

Discretionary Trading P&L

Holdings

Transaction History (15 total)

CUE
Cue Biopharma, Inc.
Oct 12, 2026
Sale(S)
Direct
10K shares at avg. $27.50$275K
CUE
Cue Biopharma, Inc.
Oct 12, 2026
Sale(S)
Direct
1.1K shares at avg. $28.05$30K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
5.4K shares at avg. $27.19$147K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
2.4K shares at avg. $28.11$67K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
10.5K shares at avg. $29.48$308K
CUE
Cue Biopharma, Inc.
Aug 12, 2026
Sale(S)
Direct
34.2K shares at avg. $26.99$924K
CUE
Cue Biopharma, Inc.
Aug 12, 2026
Sale(S)
Direct
5.8K shares at avg. $27.75$160K
CUE
Cue Biopharma, Inc.
Aug 12, 2026
Exercise(M)
Direct
109.2K shares-
CUE
Cue Biopharma, Inc.
Jul 9, 2026
Award(A)
Direct
327.5K shares-
CUE
Cue Biopharma, Inc.
Jun 1, 2026
Award(A)
Pre-Funded Warrants (Right to Buy)
Indirect
90.9K shares at avg. $11.00-
CUE
Cue Biopharma, Inc.
Jun 1, 2026
Award(A)
Common Stock Warrants (Right to Buy)
Indirect
45.5K shares-
CUE
Cue Biopharma, Inc.
Jun 1, 2026
Purchase(P)
Pre-Funded Warrants (Right to Buy)
Indirect
90.9K shares at avg. $11.00-
CUE
Cue Biopharma, Inc.
Jun 1, 2026
Purchase(P)
Common Stock Warrants (Right to Buy)
Indirect
45.5K shares-
CUE
Cue Biopharma, Inc.
May 3, 2026
Award(A)
Direct
327.5K shares-
SRZN
Surrozen, Inc./DE
May 14, 2025
Award(A)
Option (right to buy)
Direct
1.3K shares-

		Type	Shares	Price		Ownership
Oct 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	10,000	$27.50	$275,000	Direct
Oct 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	1,087	$28.05	$30,490	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	5,423	$27.19	$147,451	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	2,375	$28.11	$66,761	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	10,460	$29.48	$308,361	Direct
Aug 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	34,225	$26.99	$923,733	Direct
Aug 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	5,775	$27.75	$160,256	Direct
Aug 12, 2026	CUE Cue Biopharma, Inc.	Exercise(M)	109,179	-	$0	Direct
Jul 9, 2026	CUE Cue Biopharma, Inc.	Award(A)	327,537	-	$0	Direct
Jun 1, 2026	CUE Cue Biopharma, Inc.	Award(A) Pre-Funded Warrants (Right to Buy)	90,906	$11.00	-	Indirect
Jun 1, 2026	CUE Cue Biopharma, Inc.	Award(A) Common Stock Warrants (Right to Buy)	45,453	-	-	Indirect
Jun 1, 2026	CUE Cue Biopharma, Inc.	Purchase(P) Pre-Funded Warrants (Right to Buy)	90,906	$11.00	-	Indirect
Jun 1, 2026	CUE Cue Biopharma, Inc.	Purchase(P) Common Stock Warrants (Right to Buy)	45,453	-	-	Indirect
May 3, 2026	CUE Cue Biopharma, Inc.	Award(A)	327,537	-	$0	Direct
May 14, 2025	SRZN Surrozen, Inc./DE	Award(A) Option (right to buy)	1,333	-	-	Direct

1-15 of 15 transactions

About Lin Shao-Lee

Lin Shao-Lee (SEC CIK 0001725092) files insider reports with the SEC as Chief Executive Officer of Cue Biopharma, Inc. (CUE) and Director of Surrozen, Inc./DE (SRZN).

Signal8 holds 8 ownership filings by Lin Shao-Lee (1 Form 3, 7 Form 4), filed between May 15, 2025 and Oct 14, 2026. Those filings report 15 transactions, from May 14, 2025 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Lin Shao-Lee's filings is in SOMERVILLE, MA.

Recent filings by Lin Shao-Lee

Oct 12, 2026: Open-market sales of CUE shares (2 lines, Form 4, code S).
Aug 13, 2026: Open-market sales of CUE shares (3 lines, Form 4, code S).
Aug 12, 2026: Open-market sales of CUE shares (2 lines, Form 4, code S).
Aug 12, 2026: Option exercise of CUE shares (Form 4, code M).
Jul 9, 2026: Grant or award of CUE shares (Form 4, code A).

Other insiders filing for Cue Biopharma, Inc. (CUE)

Ray Sumita, Chief Legal Compliance Officer
Meluzio Michael Vincent, VP, Prin. Accounting Officer
Sarraf Pasha, Director
Garzone Pamela, Director
Ahlers James M, Chief Financial Officer
Borie Dominique Christian, Chief Medical Officer

How to read Form 4 transaction codes